Skip to content

A study to assess whether curcumin can maintain remission in Rheumatoid arthritis while tapering disease modifying anti- rheumatic drugs

A study to assess the efficacy of curcumin as an immunomodulator in Rheumatoid arthritis

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013279
Enrollment
200
Registered
2018-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Rheumatoid arthritis Health Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement Health Condition 3: M060- Rheumatoid arthritis without rheumatoid factor

Interventions

Intervention1: Curcumin - piperine tablet: Curcumin - piperine tablet Dose - 1gram twice daily for 12 months Control Intervention1: Placebo: 1 gram bd

Sponsors

Dr Padmanabha Shenoy D
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria On conventional DMARDs for at least last six months. On sustained remission based on DAS 28 (DAS 28 Documented remission status at a minimum of two consecutive visits during last 6 months .

Exclusion criteria

Exclusion criteria: Having other associated rheumatological diseases Functional class IV Abnormal liver function (defined as AST/ALT > 3 X upper normal limit ) and active hepatits/cirrhosis Abnormal renal function / chronic renal failure ( S. creatinine � 2mg/dl) Those who are currently on curcumin supplements Known allergic reaction to curcumin Major comorbidities like severe hypertension , uncontrolled diabetes mellitus , severe respiratory or cardiovascular disease , malignancy Current or past use of biologics Current use of Warfarin Subjects with acute episodes of cholecystitis within last few months Pregnant and lactating women Psychiatric or mental disorders

Design outcomes

Primary

MeasureTime frame
Number of flare and time to flare in placebo and curcumin arm will be comparedTimepoint: 1 YEAR

Secondary

MeasureTime frame
1.Cytokine levels ( MBDA assay: multibiomarkerdisease activity (MBDA) score ) which is a validated score of 12 cytokines will be done in patients who have flared and those who are in remission to see which are the cytokines suppressed by curcumin to maintain remission 2.Change in DAS 28 in placebo and curcumin arm 3.Change in HAQ DI in placebo and curcumin arm Timepoint: 1 YEAR

Countries

India

Contacts

Public ContactDr Padmanabha Shenoy D

Centre for arthritis and Rheumatism Excellence (CARE), Sree Sudheendra Medical Mission

drdpshenoy@gmail.com9446567000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 10, 2026